| 1 |
34784541 | Transitional cell metaplasia of the uterine cervix: A histopathological and immunohistochemical analysis suggesting a possible role of androgenic conversion during urothelial-like differentiation in peri/postmenopausal women. | 2022 Feb |
2 |
| 2 |
34661039 | Serum Testosterone to Androstenedione Ratio Predicts Metabolic Health in Normal-Weight Polycystic Ovary Syndrome Women. | 2021 Nov 1 |
2 |
| 3 |
33111427 | Design, Synthesis and Cytotoxicity Evaluation of Novel Indole Derivatives Containing Benzoic Acid Group as Potential AKR1C3 Inhibitors. | 2020 Dec |
4 |
| 4 |
29602039 | Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid. | 2018 Apr 25 |
1 |
| 5 |
29936123 | 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer. | 2018 Oct |
1 |
| 6 |
28190856 | Virilism and Ectopic Expression of HSD17B5 in Mature Cystic Teratoma. | 2017 Feb |
1 |
| 7 |
25514466 | The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. | 2015 Jun 5 |
1 |
| 8 |
26312838 | Effect of insulin on AKR1C3 expression in female adipose tissue: in-vivo and in-vitro study of adipose androgen generation in polycystic ovary syndrome. | 2015 Feb 26 |
1 |
| 9 |
24771350 | Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. | 2014 Oct |
1 |
| 10 |
24771644 | Canonical androstenedione reduction is the predominant source of signaling androgens in hormone-refractory prostate cancer. | 2014 Nov 1 |
1 |
| 11 |
24787657 | Understanding androgen action in adipose tissue. | 2014 Sep |
3 |
| 12 |
24981575 | In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). | 2014 Oct |
2 |
| 13 |
22265960 | Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride. | 2012 May |
1 |
| 14 |
20036328 | Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer. | 2010 Feb 15 |
1 |
| 15 |
20086173 | Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. | 2010 Feb 1 |
1 |
| 16 |
18692800 | Association of the 17-hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) with hyperandrogenemia in polycystic ovary syndrome (PCOS). | 2009 Aug |
1 |
| 17 |
19022235 | Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines. | 2009 Mar 16 |
1 |
| 18 |
19250190 | Steroid hormone transforming aldo-keto reductases and cancer. | 2009 Feb |
1 |
| 19 |
19336506 | Type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in the adrenal reticularis. | 2009 Jun |
2 |
| 20 |
17950253 | An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. | 2008 Jan 15 |
2 |
| 21 |
16510604 | Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. | 2006 Mar 1 |
2 |
| 22 |
16601286 | Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. | 2006 Mar |
1 |
| 23 |
16735089 | Paracrine-stimulated gene expression profile favors estradiol production in breast tumors. | 2006 Jul 11 |
2 |
| 24 |
15582534 | Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. | 2004 Dec |
1 |
| 25 |
10998348 | Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. | 2000 Oct 1 |
4 |